Apellis Pharmaceuticals, Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between January 28, 2021 and July 28, 2023, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 2, 2023.

If you purchased Apellis common stock during the Class Period and would like to join the prospective action, please click “Join This Class Action.”

Class Period:January 28, 2021 through July 28, 2023
If you purchased Apellis common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of the case:

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:

  • SYFOVRE’s (an intravitreal pegcetacoplan injection which is the first and only approved therapy for geographic atrophy (“GA”), a leading cause of blindness) design of  clinical trials was insufficient to identify incidents of retinal vasculitis in patients receiving SYFOVRE injections;
  • as a result, the commercial adoption of SYFOVRE was subject to significant, unknown risk factors; and
  • therefore, defendants’ statements about Apellis’ business, operations, and prospects lacked a reasonable basis.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Follow us on:
Company Name: Apellis Pharmaceuticals, Inc.
Stock Symbol: APLS
Class Period: January 28, 2021 through July 28, 2023
Court: United States District Court District of Delaware

Why Rosen Law

The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.

Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.

Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.

The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.

Scroll to Top